FY2025 · ended Dec 31, 2025 · Revenue $1.54M, -78.0% YoY · Filed Feb 25, 2026
Celldex Therapeutics, Inc. (CLDX) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.5 million and a net loss of $258.8 million. Free cash flow was -$213.7 million. As of Jun 30, 2026 it held $717.6 million in cash and investments and $4.9 million in total debt.
Revenue (TTM)
$158,000
-97.3% vs year-ago TTM
Net income (TTM)
$-300.55M
Operating cash flow (TTM)
$-235.57M
-26.5% vs year-ago TTM
Free cash flow (TTM)
$-242.10M
-28.4% vs year-ago TTM
EPS (TTM)
$-4.34
-111.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
66.57M
+0.3% vs prior year
Net cash
$712.68M
as of Jun 30, 2026
Operating margin
-206220.3%
FY 2026
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- CLDX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Hampton, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 744218
- Former names
- AVANT IMMUNOTHERAPEUTICS INC (until Sep 29, 2008); T CELL SCIENCES INC (until Aug 21, 1998)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.5M | $7.0M | $6.9M | $2.4M | $4.7M |
| Operating income | -$287.4M | -$195.1M | -$154.5M | -$115.2M | -$71.2M |
| Net income | -$258.8M | — | — | — | — |
| Diluted EPS | -$3.90 | -$2.45 | -$2.92 | -$2.40 | -$1.64 |
| Operating cash flow | -$210.9M | -$157.8M | -$107.3M | -$103.7M | -$60.9M |
| Free cash flow | -$213.7M | -$159.7M | -$109.1M | -$105.6M | -$62.2M |
| Total assets | $583.0M | $792.3M | $465.6M | $352.7M | $444.7M |
| Total liabilities | $55.8M | $45.3M | $36.5M | $26.5M | $25.2M |
| Stockholders' equity | $527.2M | $747.0M | $429.2M | $326.2M | $419.5M |
| Cash and investments | $518.6M | $725.3M | $423.6M | $305.0M | $408.2M |
| Total debt | $2.3M | $3.8M | $2.5M | $4.0M | $3.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Sep 22, 2026 | Sep 22, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 15, 2026 | Jul 10, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 26, 2026 | Jun 25, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
All 1000 Celldex Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.